IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

Stephen P. Hack, Jessica Spahn, Minshan Chen, Ann Lii Cheng, Ahmed Kaseb, Masatoshi Kudo, Han Chu Lee, Adam Yopp, Pierce Chow, Shukui Qin

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT0410209.

Original languageEnglish (US)
Pages (from-to)975-989
Number of pages15
JournalFuture Oncology
Volume16
Issue number15
DOIs
StatePublished - May 2020

Keywords

  • Ablation
  • Adjuvant treatment
  • Atezolizumab
  • Bevacizumab
  • Hepatocellular carcinoma
  • PD-L1
  • Recurrence-free survival
  • Resection
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation'. Together they form a unique fingerprint.

  • Cite this